Sutro Biopharma (STRO) Financials

Sutro Biopharma’s financial profile remains under pressure, although operating costs and cash burn have improved from early 2025 levels. The company generated $9.8 million of revenue in Q2 2026, down from $14.5 million in Q1 2026 and $63.7 million in the restated Q2 2025 period. Revenue has been volatile, which is typical of a biotechnology company that relies heavily on collaboration and milestone payments rather than recurring product sales.

Net loss was $38.5 million in Q2 2026, roughly unchanged from Q1 2026 but significantly worse than the $11.5 million restated loss in Q2 2025. Still, total operating expenses declined to $39.7 million from $67.1 million a year earlier, helped by lower research and development, selling, general and administrative, and restructuring costs.

Liquidity has also weakened over the longer period. Cash and short-term investments totaled $164.0 million at June 30, 2026, down from $248.5 million at June 30, 2025 and $388.3 million at September 30, 2024. Based on Q2 operating cash burn of $38.3 million, the company held roughly four quarters of cash and short-term investments before considering any additional financing, revenue, or spending changes.

• Operating cash burn improved: Net cash used in operating activities was $38.3 million in Q2 2026, compared with $44.7 million in Q2 2025 and $67.9 million in Q1 2025.
• Cost controls are taking effect: Total operating expenses fell to $39.7 million in Q2 2026 from $67.1 million in the restated Q2 2025 period. SG&A declined to $7.8 million, while R&D spending declined to $31.7 million.
• Recent equity financing strengthened liquidity: Sutro raised approximately $103.2 million through common equity issuance in Q1 2026, helping offset operating and investing cash outflows.
• Debt exposure appears limited: The supplied balance sheets show no short-term or long-term debt in the recent periods, reducing traditional debt-service and refinancing risk.
• Investment activity is driving large cash-flow swings: Sutro frequently purchases and sells short-term investments. Q2 2026 investing activities provided $19.4 million of cash, but this largely reflected investment maturities and sales rather than operating profitability.
• Interest expense remains significant: Q2 2026 interest expense was $10.4 million, partially offset by $1.7 million of interest and investment income. This line item continues to weigh on pretax results despite the absence of reported traditional debt balances.
• Revenue has sharply deteriorated: Q2 2026 revenue of $9.8 million was approximately 85% below the restated Q2 2025 revenue of $63.7 million and was also below Q2 2024 revenue of $25.7 million.
• The company remains deeply unprofitable: Sutro has reported recurring quarterly net losses, including losses of $38.5 million in both Q1 and Q2 2026. Retained earnings were negative $1.05 billion at June 30, 2026.
• Shareholder equity has turned negative: Total equity declined from positive $152.2 million in Q2 2024 to negative $103.3 million in Q2 2026, while total liabilities of $297.8 million exceeded total assets of $194.5 million.
• Additional financing may be needed: Cash and short-term investments fell by approximately $84.5 million year over year, and Q2 2026 ended with a $19.3 million decline in cash. Continued operating losses could require additional equity issuance, asset sales, or other financing and could dilute existing shareholders.

Overall, Sutro’s lower operating expenses and improved cash burn are constructive, but they have not yet translated into sustainable revenue growth or profitability. The most important issues for investors are the sharp decline in collaboration-related revenue, negative equity, continued quarterly losses, and the company’s ability to fund its pipeline without substantial dilution.